ATE440821T1 - Isochinolinderivate als mao-b inhibitoren - Google Patents

Isochinolinderivate als mao-b inhibitoren

Info

Publication number
ATE440821T1
ATE440821T1 AT03725018T AT03725018T ATE440821T1 AT E440821 T1 ATE440821 T1 AT E440821T1 AT 03725018 T AT03725018 T AT 03725018T AT 03725018 T AT03725018 T AT 03725018T AT E440821 T1 ATE440821 T1 AT E440821T1
Authority
AT
Austria
Prior art keywords
mao
inhibitors
isoquinoline derivatives
isoquinoline
derivatives
Prior art date
Application number
AT03725018T
Other languages
English (en)
Inventor
Andrea Cesura
Sarmiento Rosa Maria Rodriguez
Michelangelo Scalone
Andrew Thomas
Rene Wyler
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE440821T1 publication Critical patent/ATE440821T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
AT03725018T 2002-04-26 2003-04-14 Isochinolinderivate als mao-b inhibitoren ATE440821T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02009253 2002-04-26
PCT/EP2003/003845 WO2003091219A1 (en) 2002-04-26 2003-04-14 Isoquinoline derivatives

Publications (1)

Publication Number Publication Date
ATE440821T1 true ATE440821T1 (de) 2009-09-15

Family

ID=29265896

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03725018T ATE440821T1 (de) 2002-04-26 2003-04-14 Isochinolinderivate als mao-b inhibitoren

Country Status (30)

Country Link
US (1) US6818774B2 (de)
EP (1) EP1501804B1 (de)
JP (1) JP4322685B2 (de)
KR (1) KR100681585B1 (de)
CN (1) CN1310890C (de)
AR (1) AR039651A1 (de)
AT (1) ATE440821T1 (de)
AU (1) AU2003227614B2 (de)
BR (1) BR0309562A (de)
CA (1) CA2483461C (de)
DE (1) DE60328978D1 (de)
DK (1) DK1501804T3 (de)
ES (1) ES2329354T3 (de)
GT (1) GT200300095A (de)
HR (1) HRP20040952A2 (de)
IL (1) IL164677A0 (de)
MX (1) MXPA04010537A (de)
MY (1) MY133527A (de)
NO (1) NO20044571L (de)
NZ (1) NZ535885A (de)
PA (1) PA8572001A1 (de)
PE (1) PE20040594A1 (de)
PL (1) PL373697A1 (de)
PT (1) PT1501804E (de)
RU (1) RU2318812C2 (de)
SI (1) SI1501804T1 (de)
TW (1) TWI278451B (de)
UY (1) UY27786A1 (de)
WO (1) WO2003091219A1 (de)
ZA (1) ZA200408281B (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0410746A (pt) * 2003-05-19 2006-06-27 Irm Llc compostos e composições imunossupressoras
EP1638551B1 (de) * 2003-05-19 2011-12-21 Irm Llc Immunosuppressive verbindungen und zusammensetzungen
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
US7825109B2 (en) 2003-08-29 2010-11-02 Ono Pharmaceutical Co., Ltd. Compound capable of binding S1P receptor and pharmaceutical use thereof
BRPI0413923A (pt) * 2003-08-29 2006-11-07 Ono Pharmaceutical Co composto capaz de ligar o receptor de s1p e uso farmacêutico do mesmo
WO2005039591A1 (en) * 2003-10-23 2005-05-06 F. Hoffmann-La Roche Ag Benzazepine derivatives as mao-b inhibitors
US7763638B2 (en) 2004-03-01 2010-07-27 Actelion Pharmaceuticals Ltd. Substituted 1,2,3,4-tetrahydroisoquinoline derivatives
EP2371811B1 (de) 2004-12-13 2014-10-08 Ono Pharmaceutical Co., Ltd. Azetidincarboxylsäurederivat und medizinische Verwendung davon
JP4934055B2 (ja) * 2005-01-28 2012-05-16 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト イソクロマンおよびその誘導体の製造方法
CN101128189A (zh) 2005-02-25 2008-02-20 弗·哈夫曼-拉罗切有限公司 药物物质分散性改善的片剂
JP5271087B2 (ja) * 2005-12-22 2013-08-21 ニユーロン・フアーマシユーテイカルズ・エツセ・ピー・アー カルシウム及び／又はナトリウムチャネル調節物質としての２−フェニルエチルアミノ誘導体
CA2644010A1 (en) * 2006-03-15 2007-09-20 Actelion Pharmaceuticals Ltd Tetrahydroisoquinoline derivatives to enhance memory function
CN101432285A (zh) 2006-04-26 2009-05-13 埃科特莱茵药品有限公司 作为食欲素受体拮抗剂的吡唑并-四氢吡啶衍生物
KR101220182B1 (ko) * 2009-02-25 2013-01-11 에스케이바이오팜 주식회사 치환된 아졸 유도체 화합물, 이를 포함하는 약제학적 조성물 및 이를 이용한 파킨슨씨 병 치료방법
CN105315204B (zh) * 2014-07-04 2018-02-09 中南大学 7‑氨基‑1,4‑二氢异喹啉‑3(2h)‑酮衍生物及其合成方法和用途
CN105461626B (zh) * 2015-12-17 2018-05-08 浙江工业大学 芳环或稠杂环联3,4-二氢异喹啉类共轭结构化合物及其应用
CN105585527B (zh) * 2015-12-17 2018-06-26 浙江工业大学 2-(3,4-二氢异喹啉-1(2h)-亚基)乙腈类化合物及其应用
CN110461829B (zh) * 2017-03-27 2023-02-28 百时美施贵宝公司 作为免疫调节剂的取代的异喹啉衍生物
JP7720847B2 (ja) * 2019-12-18 2025-08-08 シーエイチディーアイ ファウンデーション，インコーポレーテッド ハンチンチンタンパク質をイメージングするための化合物及びプローブ
CN114591238B (zh) * 2022-03-25 2022-11-15 邦恩泰(山东)生物医药科技集团股份有限公司 一种异喹啉类药物中间体的合成方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6137002A (en) * 1993-07-22 2000-10-24 Eli Lilly And Company Glycoprotein IIb/IIIa antagonists
IL110172A (en) * 1993-07-22 2001-10-31 Lilly Co Eli Bicyclic compounds and pharmaceutical compositions containing them
US6448269B1 (en) * 1993-07-22 2002-09-10 Eli Lilly And Company Glycoprotein IIb/IIIa antagonists
US5731324A (en) * 1993-07-22 1998-03-24 Eli Lilly And Company Glycoprotein IIb/IIIa antagonists
US5679715A (en) 1995-06-07 1997-10-21 Harris; Richard Y. Method for treating multiple sclerosis
WO1997033572A1 (en) 1996-03-15 1997-09-18 Somerset Pharmaceuticals, Inc. Method for preventing and treating peripheral neurophathy by administering selegiline
WO2001034172A2 (en) 1999-11-05 2001-05-17 Vela Pharmaceuticals Inc. Methods and compositions for treating reward deficiency syndrome

Also Published As

Publication number Publication date
JP4322685B2 (ja) 2009-09-02
BR0309562A (pt) 2005-02-15
PT1501804E (pt) 2009-10-29
GT200300095A (es) 2004-01-15
TW200307670A (en) 2003-12-16
TWI278451B (en) 2007-04-11
ZA200408281B (en) 2005-10-14
IL164677A0 (en) 2005-12-18
AU2003227614A1 (en) 2003-11-10
AR039651A1 (es) 2005-03-02
MXPA04010537A (es) 2005-01-25
EP1501804A1 (de) 2005-02-02
MY133527A (en) 2007-11-30
US20030225122A1 (en) 2003-12-04
RU2318812C2 (ru) 2008-03-10
PA8572001A1 (es) 2003-12-10
UY27786A1 (es) 2003-10-31
EP1501804B1 (de) 2009-08-26
HK1080836A1 (en) 2006-05-04
US6818774B2 (en) 2004-11-16
NO20044571L (no) 2004-10-22
CA2483461C (en) 2010-12-21
NZ535885A (en) 2007-05-31
CA2483461A1 (en) 2003-11-06
HRP20040952A2 (en) 2005-06-30
KR20040104628A (ko) 2004-12-10
RU2004134575A (ru) 2005-07-20
DK1501804T3 (da) 2009-10-12
CN1310890C (zh) 2007-04-18
JP2005533761A (ja) 2005-11-10
CN1649844A (zh) 2005-08-03
PL373697A1 (en) 2005-09-05
ES2329354T3 (es) 2009-11-25
SI1501804T1 (sl) 2009-12-31
WO2003091219A1 (en) 2003-11-06
KR100681585B1 (ko) 2007-02-09
AU2003227614B2 (en) 2008-06-26
DE60328978D1 (de) 2009-10-08
PE20040594A1 (es) 2004-08-30

Similar Documents

Publication Publication Date Title
ATE452891T1 (de) Pyrimidopyrimidone als kinaseinhibitoren
ATE437862T1 (de) Pyrimidin-5-onderivate als ldl-pla2 inhibitoren
DE60325032D1 (de) 2-hydroxy-3-heteroarylindole derivate als gsk3 inhibitoren
DE60329282D1 (de) Cyano-pyrrolidine als DPP-IV Inhibitoren
DE60320933D1 (de) Rho-kinase inhibitoren
DE60313872D1 (de) Pyrazoloä1,5-aüpyrimidine als hemmstoffe cyclin-abhängiger kinasen
ATE478870T1 (de) Spiroindolinpiperidinderivate
ATE460418T1 (de) Heterocyclocarboxamidderivate
DK1551802T3 (da) Indol-3-svovlderivater
ATE467631T1 (de) Chinuclidinamidderivate
ATE438644T1 (de) Chinazolinderivate
IS7720A (is) Píperidín-N-oxíð-afleiður
DK1474408T3 (da) N-Phenyl-2-pyrimidinaminderivater
DK1505963T3 (da) Hepatitis C-inhibitorer
DE50304983D1 (de) Heteroaryloxy-substituierte phenylaminopyrimidine als rho-kinaseinhibitoren
ATE437876T1 (de) Hexahydropyridoisochinoline als dpp-iv- inhibitoren
DE602004018837D1 (de) Ptidase-iv-inhibitoren
DE60315862D1 (de) Dihydropyridinonderivate als hne-inhibitoren
ATE529428T1 (de) Thioxanthinderivate als myeloperoxidaseinhibitoren
ATE440821T1 (de) Isochinolinderivate als mao-b inhibitoren
IS8180A (is) Nýjar besímídasólafleiður
ATE411306T1 (de) Biarylsulfonamide als mmp-inhibitoren
ATE402700T1 (de) Glycinamid-derivate als raf-kinase-hemmer
DE502004006055D1 (de) 6-arylamino-5-cyano-4-pyrimidinone als pde9a-inhibitoren
ATE335729T1 (de) 3h-chinazoline -4-on derivaten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1501804

Country of ref document: EP

REN Ceased due to non-payment of the annual fee